Arbutus Biopharma
ABUS
ABUS
80 hedge funds and large institutions have $79.4M invested in Arbutus Biopharma in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
2.87% less ownership
Funds ownership: 29.12% → 26.25% (-2.9%)
32% less call options, than puts
Call options by funds: $4.67M | Put options by funds: $6.87M
Holders
80
Holding in Top 10
–
Calls
$4.67M
Puts
$6.87M
Top Buyers
| 1 | +$2.75M | |
| 2 | +$1.8M | |
| 3 | +$1.55M | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.22M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$906K |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$5.28M | |
| 3 | -$691K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$400K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$139K |